Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly sales of $149.390 million which beat the analyst consensus estimate of $148.174 million by 0.82 percent. This is a 5.63 percent increase over sales of $141.421 million the same period last year.